Shine-On BioMedical Co., Ltd.

Shine-On BioMedical Co., Ltd. is a biotechnology company focused on innovative cancer drug development. Established in 2021 and headquartered in Taichung, Taiwan, the company specializes in the research, development, and manufacturing of anti-cancer therapeutics, particularly multi-specific antibody drugs and nucleic acid-based therapies. Shine-On BioMedical’s portfolio features several pioneering products, including trispecific T cell engaging nanobodies, engineered exosome drug delivery systems, and adaptive immune cell antibodies. Its technology platforms, notably the “Tri-Specific Antibody with T-cell Engager” and “Targeted Exosome for Drug Delivery,” have led to the development of five "First-in-Human" drugs, positioning Shine-On BioMedical at the forefront of targeted cancer treatment. Operating within the broader healthcare and biotechnology sectors, the company's mission is to advance effective cancer therapy options through sophisticated biologics and molecular approaches. Shine-On BioMedical plays a significant role in Taiwan’s emerging biomedical industry, driving progress and innovation in oncology research and pharmaceutical technology.